Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Camoquin Hydrochloride (amodiaquine hydrochloride) is an oral antimalarial tablet in pre-launch development by Pfizer. Amodiaquine is a 4-aminoquinoline compound historically used to treat malaria and some parasitic infections. The drug works by interfering with parasite protein synthesis and DNA replication within infected red blood cells.
Pre-Launch
Early-stage commercial opportunity with potential for significant team expansion in regulatory, medical affairs, and field operations upon approval.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Camoquin at pre-launch presents a ground-floor opportunity to shape the brand strategy and infrastructure from inception. Career growth potential is high as the organization builds commercial capabilities for global health markets with WHO partnerships.
Regulatory Affairs SpecialistMedical Science Liaison
Worked on CAMOQUIN HYDROCHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.